Skip to content
Biodatica
Start free

Bolt Biotherapeutics, Inc.

Palo Alto, California

OncologyPhase IIListed · BOLT

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

5mo agoTrial registeredJan 27, 2026Source filing (opens the source filing in a new tab)

Momentum

67no change

Momentum 67 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    May 26, 2025

    Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma · RECRUITING · sponsor: Bolt Biotherapeutics, Inc. · A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

    ClinicalTrials.gov · NCT06921837 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Oct 11, 2023

    Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma · TERMINATED · sponsor: Bolt Biotherapeutics, Inc. · Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

    ClinicalTrials.gov · NCT06052852 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources